As a whole, how is biopharma performing compared to expectations in Q2?

I was wondering how biopharma as a whole has been performing compared to expected EPS for Q2 of FY2023… also, if you have any future tips for finding sources for this kind of stuff, feel free to let me know. I’m looking for aggregations by industry.